Cartesian Therapeutics price to book ratio RNAC

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 1.8×; Mar 2024
10-year median: 4.3×
10-year range: 1.6× to 28.0×
Peer median: 1.6×

Cartesian Therapeutics' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Mar 2024, at 1.8×.

On the days it had one over the last ten years, its median was 4.3×, from 1.6× in Jan 2024 to 28.0× in Apr 2020.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	1.8×	1.6×	2.2×
2023	1.8×	1.8×	3.4×
2022	2.0×	1.8×	9.1×
2021	n/m a value too high to mean anything
2020	26.8×	17.8×	28.0×
2019	6.0×	3.7×	7.2×
2018	6.5×	2.9×	14.4×
2017	3.4×	3.1×	9.0×
2016	4.8×	2.9×	7.3×

Against its peers

Companies in Drug Manufacturers - General nearest Cartesian Therapeutics' size, closest first, today.

Company	Price to book ratio
RNACCartesian Therapeutics	n/m
NATRNatures Sunshine Products	1.3×
LFVNLifevantage	2.2×
ARVNArvinas	0.8×
SPROSpero Therapeutics	1.5×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
ATNMActinium Pharmaceuticals	1.6×
COLLCollegium Pharmaceutical	2.4×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Cartesian Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.